Pharmacodynamics and clinical use of anti-HIV drugs

被引:3
作者
Preston, SL
Piliero, PJ
Drusano, GL
机构
[1] Albany Med Coll, Div Clin Pharmacol, Clin Res Inst, Albany, NY 12208 USA
[2] Albany Med Coll, Ordway Res Inst, Albany, NY 12208 USA
关键词
D O I
10.1016/S0891-5520(03)00064-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Administration of antiretroviral agents is a cornerstone of therapy for HIV infection and combination therapy is a key to the decreased HIV-associated morbidity and mortality seen since the late 1990s. Appropriate dosing of these agents has become increasingly complex because of the use of combinations of drugs referred to as highly active antiretroviral therapy. These regimens are often associated with an increased likelihood for drug-drug interactions and overlapping toxicity profiles. To dose these drugs most appropriately, the pharmacodynamic relationships between these drugs must be understood and then applied in general clinical practice to evaluate outcome.
引用
收藏
页码:651 / +
页数:25
相关论文
共 102 条
[1]   Position paper on therapeutic drug monitoring of antiretroviral agents [J].
Acosta, EP ;
Gerber, JG .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (12) :825-834
[2]   Indinavir plasma protein binding in HIV-1-infected adults [J].
Anderson, PL ;
Brundage, RC ;
Bushman, L ;
Kakuda, TN ;
Remmel, RP ;
Fletcher, CV .
AIDS, 2000, 14 (15) :2293-2297
[3]   Therapeutic drug monitoring in HIV infection: current status and future directions [J].
Back, D ;
Gatti, G ;
Fletcher, C ;
Garaffo, R ;
Haubrich, R ;
Hoetelmans, R ;
Kurowski, M ;
Luber, A ;
Merry, C ;
Perno, CF .
AIDS, 2002, 16 :S5-S37
[4]   Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults [J].
Bartlett, JA ;
DeMasi, R ;
Quinn, J ;
Moxham, C ;
Rousseau, F .
AIDS, 2001, 15 (11) :1369-1377
[5]   Human serum alpha(1) acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease [J].
Bilello, JA ;
Bilello, PA ;
Stellrecht, K ;
Leonard, J ;
Norbeck, DW ;
Kempf, DJ ;
Robins, T ;
Drusano, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1491-1497
[6]   EFFECT OF 2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE IN AN IN-VITRO HOLLOW-FIBER PHARMACODYNAMIC MODEL SYSTEM CORRELATES WITH RESULTS OF DOSE-RANGING CLINICAL-STUDIES [J].
BILELLO, JA ;
BAUER, G ;
DUDLEY, MN ;
COLE, GA ;
DRUSANO, GL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) :1386-1391
[7]   Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals [J].
Burger, D ;
Hugen, P ;
Reiss, P ;
Gyssens, I ;
Schneider, M ;
Kroon, F ;
Schreij, G ;
Brinkman, K ;
Richter, C ;
Prins, J ;
Aarnoutse, R ;
Lange, J .
AIDS, 2003, 17 (08) :1157-1165
[8]   Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations [J].
Burger, DM ;
Hugen, PWH ;
Aarnoutse, RE ;
Hoetelmans, RMW ;
Jambroes, M ;
Nieuwkerk, PT ;
Schreij, G ;
Schneider, MME ;
van der Ende, ME ;
Lange, JMA .
THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :73-80
[9]   Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen [J].
Casado, JL ;
Moreno, S ;
Hertogs, K ;
Dronda, F ;
Antela, A ;
Dehertogh, P ;
Perez-Elías, MJ ;
Moreno, A .
AIDS, 2002, 16 (01) :47-52
[10]  
CHEESEMAN SH, 1995, J ACQ IMMUN DEF SYND, V8, P141